Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 5Sarcoma 1Gastrointestinal 1Dermatologic 1

Conditions

Colorectal Neoplasms 4Neoplasm Metastasis 2Carcinoma 2Adenocarcinoma 2Stomach Neoplasms 1Recurrence 1Rectal Neoplasms 1Pancreatic Neoplasms 1Melanoma 1Liver Neoplasms 1Glioblastoma 1Esophageal Neoplasms 1Carcinoma, Squamous Cell 1Carcinoma, Pancreatic Ductal 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1

Interventions

Bevacizumab 6Nivolumab 5pembrolizumab 4Gemcitabine 4Cisplatin 3regorafenib 2fludarabine 2Sorafenib 2Paclitaxel 2Oxaliplatin 2Leucovorin 2Irinotecan 2Fluorouracil 2Drug Therapy 2Cyclophosphamide 2Azacitidine 2vocimagene amiretrorepvec 1ulixertinib 1temsirolimus 1spartalizumab 1sonidegib 1selinexor 1sargramostim 1sacituzumab govitecan 1ruxolitinib 1rucaparib 1pazopanib 1olutasidenib 1olaparib 1motexafin gadolinium 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Glioblastoma × selinexor × Gastrointestinal × Clear all
NCT01607905 2023-01-26

Safety Study of KPT-330 (Selinexor) in Patients With Advanced or Metastatic Solid Tumor Cancer

Karyopharm Therapeutics Inc

Phase 1 Completed
192 enrolled 29 charts
CNSDermatologicGastrointestinal

Adenocarcinoma, Carcinoma, Squamous Cell, Glioblastoma, Melanoma, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡